摘要
目的:研究影响Ⅰ期胃癌患者预后的临床病理和分子生物学参数,建立判断Ⅰ期胃癌预后的分子生物学模型。方法:采用免疫组化方法检测Ⅰ期胃癌患者肿瘤组织中HER2、EGFR、VEGF、p53、PCNA、ANXA1和p-mTOR的表达情况,分析其与临床病理学参数及胃癌患者预后的关系。结果:单因素分析结果表明:(1)患者年龄越大,生存期越短。(2)合并肿瘤相关性贫血患者较无贫血患者平均生存期缩短。(3)EGFR和p-mTOR表达阳性患者平均生存时间缩短。多因素分析结果表明,患者年龄、肿瘤相关性贫血、EGFR、p-mTOR及综合评分可以作为Ⅰ期胃癌预后的独立因素。结论:建立Ⅰ期胃癌预后的分子生物学模型可指导临床制定个体化的治疗方案,有助于提高Ⅰ期胃癌患者的生存率。
Objective：To establish a bio-clinicopathological model of prognosis of patients with gastric cancer at stage Ⅰ by investigating the relationship between the clinicopathological and biological parameters with the survival time. Metbods：Immunohistochemistry was used to detect the expression of HER2, EGFR, VEGF, p53, PCNA, ANXA1, and p-mTOR in gastric cancer specimens at stage Ⅰ. Statistics were used to analyze their relations with clinicopathological and biological parameters. Results：Kaplan-Meier curves showed that patients with an old age, anemia, over-expression of EGFR and p-mTOR had a poor outcome than those a young age, negative-expression of EGFR and p-mTOR, and without anemia. Multivariate analysis also showed that these factors were independent prognostic factors of gastric carcinoma. Conclusion： A bio-clinicopathological model of prognosis of patients with gastric cancer at stage Ⅰ was constructed, which might be used to instruct the personal treatment of gastric cancer patients and to improve their survival durations.
出处
《临床肿瘤学杂志》
CAS
2009年第2期123-126,共4页
Chinese Clinical Oncology
